ஜே யோங் அஹ்ன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஜே யோங் அஹ்ன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஜே யோங் அஹ்ன் Today - Breaking & Trending Today
Ian Haydon, Institute for Protein Design In this ultrapotent COVID-19 vaccine candidate, 60 coronavirus protein pieces are arrayed on a nanoparticle. A. ....
SK bioscience secures CEPI funds for Phase III Covid-19 vaccine trial 25 May 2021 (Last Updated May 25th, 2021 12:26) SK bioscience to receive up to $173.4m from CEPI to support the Phase III trial of its Covid-19 vaccine candidate, GBP510. Share Article In this ultrapotent Covid-19 vaccine candidate, 60 coronavirus protein pieces are arrayed on a nanoparticle. Credit: Ian Haydon/Institute for Protein Design. South Korea-based SK bioscience is set to receive up to $173.4m (KRW200bn) in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the Phase III trial of its Covid-19 vaccine candidate, GBP510. The funds will also be used for other development work related to the vaccine, including regulatory activities, commercial processes development, buying raw materials and research and development on response to variants. ....
Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....
IVI-SK s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®. Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....